Key result
A drug treatment-based asthma severity measure demonstrated excellent reliability between two successive time periods (kappa = 0.82) and successfully identified children with higher healthcare utilization.
Why the study?
Is a drug treatment-based asthma severity measure reliable and valid when applied to health care administrative data in children?
Cohort (n=16,862)
Is a drug treatment-based asthma severity measure reliable and valid when applied to health care administrative data in children?
A drug treatment-based severity measure for childhood asthma using prescription data is reliable and valid for pharmacoepidemiological research.
Answers are grounded in this paper and cite their sources.
Supports use of claims data for pediatric asthma severity classification; leaves open prospective validation before clinical adoption.
Valid measures of severity are crucial in asthma pharmacoepidemiological research. This study reports the development and validation of a severity measure in childhood asthma for application to health care administrative data. A drug treatment-based asthma severity measure was developed following the stepped care approach to treatment, and this was applied to a cohort of 16,862 children who met a case definition for asthma drug prescription use between January 1995 and March 1996. Assessments were made of the measure's reliability, validity, and responsiveness to change over time. The drug treatment-based asthma severity measure classified 42% of children as having mild asthma, 37% as having moderate asthma, 19% as having moderate-severe asthma, and 2% as having severe asthma. Agreement on severity classification between two successive time periods was excellent (kappa = 0.82). Children classified as having severe asthma were significantly more likely than children with mild-moderate asthma to have previous asthma hospitalizations, to visit asthma specialists, to have high physician utilization, and to require hospital critical care. They were more likely to be reclassified as having severe asthma 2 years later. These findings show that a drug treatment-based severity measure in childhood asthma, which can be applied to prescription data, has good reliability and validity, and is responsive to changes in asthma severity over time.
No takes yet. Share an insight, caveat, or question.
Kozyrskyj et al. (2002) conducted a cohort in Childhood asthma (n=16,862). Drug treatment-based asthma severity measure was evaluated on Agreement on severity classification between two successive time periods (kappa = 0.82). A drug treatment-based asthma severity measure demonstrated excellent reliability between two successive time periods (kappa = 0.82) and successfully identified children with higher healthcare utilization.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: